September 17, 2025 — Leads & Copy — Enveric Biosciences (NASDAQ: ENVB) announced the publication of two peer-reviewed research papers detailing innovative bioproduction strategies for creating therapeutic compounds. The papers, published in ACS Chemical Biology and BioDesign Research, highlight the company’s scientific leadership in pioneering bioproduction approaches that expand the tools available for drug discovery.
The first paper, “Bioproduction of a Large-Scale Library of Tryptamine Derivatives for Neuropsychiatric Drug Screening,” describes how researchers engineered microbial systems to produce 279 compounds, including 17 novel N-acetylated molecules tested for activity across receptors linked to psychiatric disease. Nearly all showed interaction with the melatonin (MT1) receptor, and several engaged serotonin receptor subtypes.
The second paper, “Bioproduction of 3,4-Methylenedioxymethamphetamine and Derivatives,” reports the first bioproduction method for MDMA and related compounds, providing a novel alternative to traditional chemical synthesis.
“These publications reflect the innovative work of our scientific team and highlight the progress being made in applying bioproduction approaches to neuropsychiatric drug discovery,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
Enveric’s lead candidate EB-003 is being advanced toward an Investigational New Drug (IND) submission, with first-in-human studies anticipated in 2026.
Contact: Joseph Tucker, Ph.D.
Source: Enveric Biosciences
